2016
Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care 2016, 39: 555-562. PMID: 26884472, PMCID: PMC4806770, DOI: 10.2337/dc15-1606.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAdolescentBlood GlucoseChildChild, PreschoolCohort StudiesCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugDouble-Blind MethodDrug-Related Side Effects and Adverse ReactionsFemaleGlucagonHumansHypoglycemiaInjections, IntramuscularInsulinMaleNauseaPowdersConceptsIntramuscular glucagonType 1 diabetesIntranasal dosesIntranasal glucagonYounger cohortsWeight-based doseMin of dosingTreatment of hypoglycemiaDose-response relationshipTransient nauseaDl riseSevere hypoglycemiaGlucagon levelsIntranasal doseClinical centersPlasma glucosePharmacodynamic studiesHospital settingGlucagon preparationPotential efficacyGlucagonType 1Adverse effectsCohortAge range
2005
Single‐ and Multiple‐Dose Pharmacokinetics of Pioglitazone in Adolescents With Type 2 Diabetes
Christensen ML, Meibohm B, Capparelli EV, Velasquez‐Mieyer P, Burghen GA, Tamborlane WV. Single‐ and Multiple‐Dose Pharmacokinetics of Pioglitazone in Adolescents With Type 2 Diabetes. The Journal Of Clinical Pharmacology 2005, 45: 1137-1144. PMID: 16172178, DOI: 10.1177/0091270005279578.Peer-Reviewed Original ResearchConceptsMultiple-dose pharmacokineticsType 2 diabetesMultiple dosingDoses of pioglitazoneDaily dose administrationTotal serum concentrationsLast doseFirst doseSystemic exposureDose administrationSerum concentrationsBlood samplesPioglitazoneDose levelsActive metaboliteDosingDoseDiabetesPharmacokineticsAdolescentsHoursActive compoundsAdministrationDoses